TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19192868

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experience sampling method (ESM)
Number of subjects: 0
Study: 15784033

Group type: EXPERIMENTAL
Intervention: IFN monotherapy for 24 weeks (group A: long-term IFN therapy)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IFN monotherapy for 6 weeks (group B: short-term IFN therapy)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IFN monotherapy for 24 weeks (group A) among patients with HCV viral load <100 kIU/ml
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IFN monotherapy for 6 weeks (group B) among patients with HCV viral load <100 kIU/ml
Number of subjects: 25
Study: 12422252

Group type: EXPERIMENTAL
Intervention: Lidocaine without preservative (active drug)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 10 mg of dimenhydrinate (active drug)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (four doses)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Codeine (active drug)
Number of subjects: 2
Study: 8537585

Group type: EXPERIMENTAL
Intervention: Strength Training (ST) using weight machines (n = 25)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET) using stationary cycles (n = 25)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Combined Strength Training and Endurance Training (ST+ET) (n = 25)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (n = 30) with no intervention
Number of subjects: 105
Study: 2816875

Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg/6 h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg/4 h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg/6 h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg/4 h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous infusion of ranitidine 0.2 mg/kg/h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous infusion of cimetidine 100 mg/h
Number of subjects: 10
Study: 1091130

Group type: EXPERIMENTAL
Intervention: 900 IU alpha-tocopherol acetate daily for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebos
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 900 IU alpha-tocopherol acetate daily
Number of subjects: 0
Study: 31455249

Group type: EXPERIMENTAL
Intervention: 8 mL ropivacaine 0.75%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 16 mL ropivacaine 0.75%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (8 mL and 16 mL)
Number of subjects: 20
Study: 28207537

Group type: EXPERIMENTAL
Intervention: Ivor‐Lewis (IL) approach
Number of subjects: 136

Group type: COMPARATOR
Intervention: Left transthoracic (LTT) approach
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Left thoracoabdominal (LTA) approach
Number of subjects: 136
Study: 26306966

Group type: EXPERIMENTAL
Intervention: Low intensity exercise programme (E) during HD sessions
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (C) receiving standard HD care
Number of subjects: 22
Study: 23736966

Group type: EXPERIMENTAL
Intervention: Voclosporin (VCS) 0.25 to 4.5 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Voclosporin (VCS) 1.5 mg/kg after fasting
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Voclosporin (VCS) 3.0 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Voclosporin (VCS)
Number of subjects: 80
Study: 21208945

Group type: EXPERIMENTAL
Intervention: Dual chamber minimal ventricular pacing (MinVP)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional dual chamber pacing (DDDR)
Number of subjects: 66
Study: 19520544

Group type: EXPERIMENTAL
Intervention: Ropivacaine (20 mL)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Saline (20 mL, Control)
Number of subjects: 66
Study: 17848841

Group type: EXPERIMENTAL
Intervention: Somatropin Powder (Sandoz)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Somatropin Solution (Sandoz)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Reference rhGH preparation
Number of subjects: 140
Study: 15025216

Group type: EXPERIMENTAL
Intervention: Coronally positioned flap (CPF) plus acellular dermal matrix (ADM) allograft
Number of subjects: 24

Group type: COMPARATOR
Intervention: Coronally positioned flap (CPF) alone
Number of subjects: 24
Study: 11831591

Group type: EXPERIMENTAL
Intervention: Dialysate with a glucose concentration of 5.5 mmol/L
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dialysate with a glucose concentration of 11 mmol/L
Number of subjects: 20
Study: 9693573

Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite and 0.2% chlorhexidine gluconate combined
Number of subjects: 10

Group type: COMPARATOR
Intervention: 2.5% sodium hypochlorite alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gluconate alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 10
Study: 7602838

Group type: EXPERIMENTAL
Intervention: Prophylactic use of Surfactant‐TA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surfactant‐TA
Number of subjects: 0
Study: 2966139

Group type: EXPERIMENTAL
Intervention: Teicoplanin (400 mg and 200 mg regimens)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Flucloxacillin (500 mg qds for five days) and Tobramycin (1.5 mg/kg initially then 80 mg tds for three days)
Number of subjects: 49
Study: 329948

Group type: EXPERIMENTAL
Intervention: Atenolol, Bendrofluazide, and Hydralazine (twice daily)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hydralazine (added to Bendrofluazide or Bendrofluazide plus Atenolol)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Atenolol and Bendrofluazide (once daily)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 39
Study: 31599225

Group type: EXPERIMENTAL
Intervention: PC-SOD 20 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PC-SOD 40 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PC-SOD 80 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PC-SOD 160 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 27621272

Group type: EXPERIMENTAL
Intervention: PAIN RelieveIt Trial intervention (details not specified)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Screening and eligibility process
Number of subjects: 223
Study: 25179585

Group type: EXPERIMENTAL
Intervention: Guided surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-guided surgery
Number of subjects: 60
Study: 23447077

Group type: EXPERIMENTAL
Intervention: Test formulation of carvedilol 25-mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Reference formulation of carvedilol 25-mg
Number of subjects: 23
Study: 22226371

Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual tablet, initial dose 100 μg, titrated to effective dose of 100 to 800 μg.
Number of subjects: 270
Study: 20667679

Group type: EXPERIMENTAL
Intervention: Prize-based contingency management (CM)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 340
Study: 17707822

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT) procedure
Number of subjects: 56

Group type: COMPARATOR
Intervention: Transobturator suburethral tape (TVT-O) procedure
Number of subjects: 56
Study: 15814550

Group type: EXPERIMENTAL
Intervention: 0-3 HLA mismatches (MM)
Number of subjects: 180

Group type: COMPARATOR
Intervention: 4-6 HLA mismatches (MM)
Number of subjects: 180
Study: 12479764

Group type: EXPERIMENTAL
Intervention: Pravastatin, 40 mg/d
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10355
Study: 9657188

Group type: EXPERIMENTAL
Intervention: Discectomy without fusion
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Fusion with autologous bone graft
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Fusion with autologous bone graft plus plating
Number of subjects: 91
Study: 8154412

Group type: EXPERIMENTAL
Intervention: Captopril treatment (2 gm/L of drinking water) for 20 days after late reperfusion
Number of subjects: 67

Group type: COMPARATOR
Intervention: Late reperfusion (reperfusion 2 hours after left coronary artery ligation)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Myocardial infarction (MI) with no treatment
Number of subjects: 67
Study: 2776168

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 30
Study: 273021

Group type: EXPERIMENTAL
Intervention: Sequential t test in experimental clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential t test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identification of subjects with consistent caries increments
Number of subjects: 0
Study: 31170812

Group type: EXPERIMENTAL
Intervention: rhPDGF-BB/β-TCP-collagen
Number of subjects: 104

Group type: COMPARATOR
Intervention: autograft
Number of subjects: 104
Study: 28453240

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir-based ART with cotrimoxazole prophylaxis
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir-based ART
Number of subjects: 156
Study: 25753869

Group type: EXPERIMENTAL
Intervention: 2.0 mm locking plate (group A, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2.0 mm non-locking plate (group B, n = 30)
Number of subjects: 60
Study: 23511357

Group type: EXPERIMENTAL
Intervention: Acupuncture (20 sessions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Valproic acid (600 mg/day)
Number of subjects: 100
Study: 21055502

Group type: EXPERIMENTAL
Intervention: 30 μg hemagglutinin (HA)
Number of subjects: 454

Group type: COMPARATOR
Intervention: 15 μg hemagglutinin (HA)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: 30 μg HA
Number of subjects: 454

Group type: COMPARATOR
Intervention: 15 μg HA
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Both 30 μg HA and 15 μg HA
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 454
Study: 19369375

Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium longum BB536 and Lactobacillus rhamnosus GG; BB536‐LGG)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 16464538

Group type: EXPERIMENTAL
Intervention: Hyperfractionated and accelerated radiochemotherapy (RCT) with 5-fluorouracil (600 mg/m²/day) and carboplatin (70 mg/m²/day) on Days 1-5 and 29-33, total RT dose of 69.9 Gy in 38 days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyperfractionated and accelerated radiotherapy (RT) alone, total RT dose of 69.9 Gy in 38 days.
Number of subjects: 0
Study: 14625604

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Esomeprazole (on-demand therapy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Omeprazole (on-demand therapy)
Number of subjects: 100
Study: 11192489

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: MTX + SSZ
Number of subjects: 54
Study: 9071477

Group type: EXPERIMENTAL
Intervention: Tiludronate (400 mg/day orally)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Etidronate (400 mg/day orally)
Number of subjects: 12
Study: 8373973

Group type: COMPARATOR
Intervention: Atracurium (0.5 mg/kg)
Number of subjects: 20
Study: 2872470

Group type: EXPERIMENTAL
Intervention: CHOP (COP plus doxorubicin)
Number of subjects: 739

Group type: COMPARATOR
Intervention: COP (cyclophosphamide, vincristine, and prednisone)
Number of subjects: 739

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 739

Group type: COMPARATOR
Intervention: COP regimen
Number of subjects: 739
Study: 29053230

Group type: EXPERIMENTAL
Intervention: Group 1: Four monthly face‐to‐face biofeedback treatments
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Group 2: One face‐to‐face biofeedback followed by telephone biofeedback
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Group 3: One face‐to‐face biofeedback followed by telephone biofeedback
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Group 4: One‐off face‐to‐face biofeedback treatment
Number of subjects: 350

Group type: COMPARATOR
Intervention: All groups (combined)
Number of subjects: 350
Study: 27011304

Group type: EXPERIMENTAL
Intervention: Manual physical therapy (3 sessions)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Surgical release/decompression of the carpal tunnel
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Manual physical therapy
Number of subjects: 120
Study: 24142187

Group type: EXPERIMENTAL
Intervention: Low financial motivation group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High financial motivation group
Number of subjects: 0
Study: 22873565

Group type: EXPERIMENTAL
Intervention: G2 (telemetry device-based follow-up)
Number of subjects: 40

Group type: COMPARATOR
Intervention: G1 (office-based follow-up)
Number of subjects: 40
Study: 20054669

Group type: EXPERIMENTAL
Intervention: Response-oriented individualized induction therapy with idarubicin (IDR) 12 mg/m2 for 3 days and cytarabine (Ara-C) 100 mg/m2 for 7 days, with additional IDR and Ara-C if bone marrow on day 8 did not become hypocellular with less than 15% blasts.
Number of subjects: 430

Group type: COMPARATOR
Intervention: Fixed-schedule induction therapy with idarubicin (IDR) 12 mg/m2 for 3 days and cytarabine (Ara-C) 100 mg/m2 for 7 days.
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Response-oriented individualized induction therapy with idarubicin (IDR) and cytarabine (Ara-C).
Number of subjects: 430

Group type: COMPARATOR
Intervention: Fixed-schedule induction therapy with idarubicin (IDR) and cytarabine (Ara-C).
Number of subjects: 430
Study: 17999182

Group type: EXPERIMENTAL
Intervention: Generalized linear model accommodating overdispersion and clustering through random effects (gamma and normal types)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimation with fully analytic integration and hybrid integration
Number of subjects: 0
Study: 16118575

Group type: EXPERIMENTAL
Intervention: Phosphatidylserine (750 mg daily for 10 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (glucose polymer, daily for 10 days)
Number of subjects: 16
Study: 12399761

Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser treatment, 3 times per week for up to 8 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control plaque (not treated)
Number of subjects: 20
Study: 10435212

Group type: EXPERIMENTAL
Intervention: Lorazepam (LO) 2 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Oxazepam (OX) 60 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lorazepam (LO)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Oxazepam (OX)
Number of subjects: 21
Study: 7796951

Group type: EXPERIMENTAL
Intervention: Live recombinant vaccinia virus expressing the major EBV membrane antigen BNLF-1 MA (gp 220-340)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (unvaccinated infants)
Number of subjects: 9
Study: 1690202

Group type: EXPERIMENTAL
Intervention: Substance P (1 pmol.kg‐1.min‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Nitroprusside (5 micrograms.kg‐1.min‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: VIP (6 pmol.kg‐1.min‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 311679

Group type: EXPERIMENTAL
Intervention: HDMTX
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: HDMTX/BCG
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Escalating doses of HDMTX
Number of subjects: 23

Group type: COMPARATOR
Intervention: BCG
Number of subjects: 23
Study: 31272903

Group type: EXPERIMENTAL
Intervention: Eosinophil counts
Number of subjects: 9789

Group type: EXPERIMENTAL
Intervention: GWAS identified rs4713354 variant (MDC1 on chromosome 6p21)
Number of subjects: 9789

Group type: EXPERIMENTAL
Intervention: Cluster analysis of subjects with elevated eosinophil counts
Number of subjects: 9789
Study: 31136545

Group type: EXPERIMENTAL
Intervention: Low-load resistance training (30% 1RM)
Number of subjects: 23

Group type: COMPARATOR
Intervention: High-load resistance training (80% 1RM)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both low-load and high-load resistance training
Number of subjects: 23
Study: 28322360

Group type: EXPERIMENTAL
Intervention: 10% CPP-ACP
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 10% CPP-ACP with 0.2% NaF (CPP-ACFP)
Number of subjects: 54
Study: 24938661

Group type: EXPERIMENTAL
Intervention: Iosimenol injection
Number of subjects: 144

Group type: COMPARATOR
Intervention: Iodixanol injection
Number of subjects: 144
Study: 23742912

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Emtricitabine + Tenofovir (FTC/TDF)
Number of subjects: 17
Study: 21461896

Group type: EXPERIMENTAL
Intervention: Nasal contact point surgery (septoplasties or submucous resections with or without partial turbinectomies)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nasal contact point surgery
Number of subjects: 42
Study: 19139053

Group type: EXPERIMENTAL
Intervention: Primigravidae
Number of subjects: 642

Group type: COMPARATOR
Intervention: Multigravidae
Number of subjects: 642
Study: 16395516

Group type: EXPERIMENTAL
Intervention: BIA measurements using Analycor 3 analyzer; TBW calculated from impedances at 50 and 100 kHz, ECW from impedance at 5 kHz.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: BIA age specific equations
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 36
Study: 14507232

Group type: EXPERIMENTAL
Intervention: Botox® (total dose 20 biological units)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study: 10427937

Group type: EXPERIMENTAL
Intervention: Leprosy-affected persons
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unaffected individuals (Control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Leprosy-affected women
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Leprosy-affected males with deformities
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Leprosy-affected females with deformities
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Economic status
Number of subjects: 100
Study: 8960843

Group type: EXPERIMENTAL
Intervention: Glibenclamide (0.33 microgram.min-1.dl-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1922860

Group type: EXPERIMENTAL
Intervention: 50 micrograms of fentanyl (group A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 25 micrograms of fentanyl (group B)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 12.5 micrograms of fentanyl (group C)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline (group D)
Number of subjects: 28
Study: 6805499

Group type: EXPERIMENTAL
Intervention: Norethisterone
Number of subjects: 23
Study: 30296169

Group type: EXPERIMENTAL
Intervention: Stress reappraisal
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Stress-is-debilitating
Number of subjects: 279

Group type: COMPARATOR
Intervention: Neutral control
Number of subjects: 279
Study: 28064433

Group type: EXPERIMENTAL
Intervention: Niobe™ ES magnetic navigation system
Number of subjects: 386

Group type: COMPARATOR
Intervention: Manual procedure
Number of subjects: 386
Study: 27382592

Group type: EXPERIMENTAL
Intervention: Self care education
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Self care education plus telephone follow-up
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 75
Study: 24114400

Group type: EXPERIMENTAL
Intervention: Calcium citrate 1 g/day
Number of subjects: 1471

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1471
Study: 22377154

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic morphologically selected sperm injection (IMSI)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 160
Study: 19363455

Group type: EXPERIMENTAL
Intervention: Fusion for nonradicular low back pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard open discectomy and microdiscectomy for radiculopathy with herniated lumbar disc
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decompressive surgery for symptomatic spinal stenosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Artificial disc replacement for single level degenerative disc disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interspinous spacer device for 1- or 2-level spinal stenosis
Number of subjects: 0
Study: 18265482

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 2437
Study: 15900109

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at dosages of 4 IU/m2/day, 6 IU/m2/day, or 8 IU/m2/day for a mean duration of 7.1 (0.4) years.
Number of subjects: 50
Study: 12510062

Group type: EXPERIMENTAL
Intervention: Single-stage bilateral Pemberton's pericapsular osteotomy with open reduction (group A1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single-stage bilateral Pemberton's pericapsular osteotomy without open reduction (group A2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single-stage bilateral Pemberton's pericapsular osteotomy (both groups A1 and A2)
Number of subjects: 20
Study: 9659155

Group type: EXPERIMENTAL
Intervention: Alosetron (0.1, 0.5, 2.0 mg, twice daily)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (first week)
Number of subjects: 27
Study: 8593549

Group type: EXPERIMENTAL
Intervention: Fortified milk (12 micrograms vitamin D3 and 1525 mg calcium per litre)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Unfortified milk (0.3 micrograms vitamin D3 and 1270 mg calcium per litre)
Number of subjects: 102
Study: 2712625

Group type: EXPERIMENTAL
Intervention: Flexible-ring annuloplasty
Number of subjects: 25

Group type: COMPARATOR
Intervention: Rigid-ring annuloplasty
Number of subjects: 25
Study: 337903

Group type: EXPERIMENTAL
Intervention: Oral methoxsalen (0.6 mg/kg) and sunlight exposure
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oral methoxsalen (0.3 mg/kg) and sunlight exposure
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo prior to whole‐body exposure
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sunlight exposure alone
Number of subjects: 51